Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Trastuzumab deruxtecan (T-DXd) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). Results on T-DXd treatment in HER2-low mBC have so far been limited to clinical trials. DESTINY-Breast Respond HER2-low Europe (NCT05945732) is a multi-center, multi-country, observational, prospective, non-interventional study planning to enroll 1350 patients from 216 sites receiving T-DXd or conventional chemotherapy as their routine clinical care for advanced stage breast cancer in 12 European countries. This non-interventional study will provide real-world insight into T-DXd treatment for HER2-low mBC with data on effectiveness, safety and tolerability, patient-reported outcomes, treatment patterns, geriatric health status and HER2 testing. This will be beneficial for improving guidance to maximize patient treatment benefit.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318675 | PMC |
| http://dx.doi.org/10.2217/fon-2024-0015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Berberine Sensitises Breast Cancer Cells to Radiation via the Attenuation of DNA Ligase III.
J Cell Mol Med
September 2025
College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Berberine (BBR) is an isoquinoline alkaloid with a variety of biological activities, including anti-microbial and anti-tumoral activities. However, the cellular targets of BBR and the roles of BBR in the radiosensitivity of breast cancer cells are not well defined. In this study, we investigated the effects of BBR on the radiosensitivity of BT549 triple-negative breast cancer cells.
View Article and Find Full Text PDFMendelian Randomization Study: The Impact of Gut Microbiota on Survival in HR+ Breast Cancer Patients Under Different Treatment Regimens Through the Modulation of Immune Cell Phenotypes.
Clin Breast Cancer
August 2025
Department of Pharmacy, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, School of Pharmacy, Fujian Medical University, Fuzhou, China. Electronic address:
Background: Emerging evidence suggests that the gut microbiota (GM) may influence the progression of breast cancer by modulating immune responses. Given the vast diversity of GM and immune cell phenotypes, this study aimed to utilize the most advanced and comprehensive data to explore the causal relationships among the GM, immune cell phenotypes, and survival rates in hormone receptor-positive (HR+) breast cancer patients under different treatment regimens.
Methods: We investigated the causal relationships between the GM, immune cell phenotypes, and survival rates in HR+ breast cancer patients treated with 11 distinct therapeutic strategies using Mendelian randomization.
Beyond Dichotomy: Considerations for Improving MRI-Based Machine Learning Models in Breast Cancer Subtyping.
Acad Radiol
September 2025
Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey (A.N.Ş.).
[Development of an AI-based Positioning Technical Assistance System for Mammography].
Nihon Hoshasen Gijutsu Gakkai Zasshi
September 2025
Department of Radiological Technology, Faculty of Health Sciences, Gifu University of Medical Science.
Purpose: We aimed to develop an AI-based system to score the positioning in mammography (MG), with the goal of establishing a foundation for future technical support.
Methods: Using 800 mediolateral oblique (MLO) images, we developed an AI model (Mask Generation Model) for automatic extraction of three regions: the pectoralis major muscle, the mammary gland region, and the nipple. Using this model, we extracted three regions from 1544 MLO images and generated mask images.
Three-dimensional histological electrophoresis with fluorescence labeling for detection of malignant tissue contours in precise conserving surgery.
Anal Chim Acta
November 2025
Department of Breast Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, PR China. Electronic address:
Background: Breast-conserving surgery (BCS) is the primary surgical approach for patients with breast cancer. The accurate determination of surgical margins during BCS is critical for patient prognosis; however, time constraints and limitations in current pathological techniques often prevent pathologists from performing this assessment intraoperatively. The inability to reliably assess margins during surgery can lead to incomplete tumor removal and the need for additional surgeries.
View Article and Find Full Text PDF